3:35 PM
 | 
Dec 05, 2017
 |  BC Extra  |  Financial News

Editas proposes $50M follow-on

Gene editing company Editas Medicine Inc. (NASDAQ:EDIT) proposed to raise $50 million in a follow-on underwritten by Morgan Stanley. Editas, which proposed the...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >